In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference.

Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages.

In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference.

Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.

In this episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu share tips for first-time attendees of the World Conference on Lung Cancer (WCLC). Recorded live at WCLC 2025, hear their 10 key recommendations to make the most of your experience, including advice on how to sneak self-care into your busy conference schedule.

LCC in Mandarin: Neoadjuvant and Perioperative Therapy for Locally Advanced NSCLC by IASLC

IASLC - ALK Positive Summit by IASLC

LCC in Greek: Virtual Tumor Board - ALK NSCLC by IASLC

Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy by IASLC

LCC in Cantonese: Novel Treatment for Advanced EGFR Mutant Lung Cancer by IASLC

FDA Approval: Zongertinib for HER2 Mutant NSCLC by IASLC